Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice by Pellegrini, L et al.
O R I G I N A L A R T I C L E
Proteomic analysis reveals co-ordinated alterations in
protein synthesis and degradation pathways in LRRK2
knockout mice
Laura Pellegrini1,2, David N. Hauser1, Yan Li3, Adamantios Mamais1,
Alexandra Beilina1, Ravindran Kumaran1, Andrea Wetzel2, Jonathon
Nixon-Abell2,4, George Heaton1,2, Iakov Rudenko5, Mor Alkaslasi1, Natalie
Ivanina1, Heather L. Melrose6, Mark R. Cookson1,† and Kirsten Harvey2,*,†
1Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute of Aging, National
Institutes of Health, Bethesda, MD 20892-3707, USA, 2Department of Pharmacology, UCL School of Pharmacy,
University College London, London WC1N 1AX, UK, 3Mass-spetrometry Facility, National Institute of
Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20982-3721, USA, 4Neurogenetics
Branch, National Institute of Neurological Disorders and Stroke – National Institutes of Health, Bethesda, MD,
USA,5Department of Neurology, SUNY at Stony Brook, Health Science Center, T12-020, Stony Brook, NY 11794-
8121, USA and 6Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
*To whom correspondence should be addressed at: UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK. Tel: þ44 02077535888;
Email: kirsten.harvey@ucl.ac.uk
Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) segregate with familial Parkinson’s disease (PD) and genetic variation
around LRRK2 contributes to risk of sporadic disease. Although knockout (KO) of Lrrk2 or knock-in of pathogenic mutations
into the mouse germline does not result in a PD phenotype, several defects have been reported in the kidneys of Lrrk2 KO
mice. To understand LRRK2 function in vivo, we used an unbiased approach to determine which protein pathways are
affected in LRRK2 KO kidneys. We nominated changes in cytoskeletal-associated proteins, lysosomal proteases, proteins in-
volved in vesicular trafficking and in control of protein translation. Changes were not seen in mice expressing the pathogenic
G2019S LRRK2 mutation. Using cultured epithelial kidney cells, we replicated the accumulation of lysosomal proteases and
demonstrated changes in subcellular distribution of the cation-independent mannose-6-phosphate receptor. These results
show that loss of LRRK2 leads to co-ordinated responses in protein translation and trafficking and argue against a dominant
negative role for the G2019S mutation.
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Introduction
Variation in the Leucine-rich repeat kinase 2 (LRRK2) gene ac-
count for a proportion of the genetic risk of Parkinson’s disease
(PD). Causative mutations in the LRRK2 gene occur in multiple
families (1–4) and genome-wide association studies nominated
the LRRK2 locus as contributing to sporadic PD risk (5–7).
LRRK2 encodes a large protein containing kinase and GTPase
enzymatic regions, which contain pathogenic mutations, sur-
rounded by multiple protein–protein interaction domains (8).
Pathogenic mutants are more active than wild-type (WT) LRRK2
in vitro and in cellular assays (9–11). As homozygous and hetero-
zygous patients carrying the G2019S mutation have similar risk
of developing PD and similar disease progression (12–14),
G2019S is a true dominant allele. Potential mechanisms include
a gain of normal function, a neomorphic function not seen in
the WT protein or a dominant negative effect. Distinguishing
whether mutant LRRK2 is pathogenic via higher or lower activ-
ity is critically important as kinase inhibitors are being devel-
oped as therapeutic agents for PD (15).
LRRK2 is implicated in vesicular trafficking (16–19), perhaps
owing to phosphorylation of Rab GTPases, key regulators in
membrane trafficking (9,20). LRRK2 is also involved in the regu-
lation of cytoskeletal dynamics (21–24), including an interaction
with b-tubulin isoforms (21). Finally, LRRK2 has been proposed
to influence protein translation (25–28) although the precise
mechanism(s) involved have not been delineated. Whether the
proposed effects on protein translation are related to vesicular
and/or cytoskeletal events are uncertain.
Transgenic or knockout (KO) mouse models do not consis-
tently recapitulate the primary PD pathologies, including loss of
dopamine neurons in the substantia nigra (18,29–31). However,
multiple groups have reported that loss of LRRK2 causes age-
dependent pathological alterations in kidneys (18,29,30,32), po-
tentially owing to high expression of Lrrk2 relative to Lrrk1 (30).
LRRK2-KO kidneys have altered texture, an increase in apoptotic
cell death and inflammation (18), and an accumulation of lipo-
fuscin (18,29,30,32) that may occur owing to altered lysosomal
function (18,29). Some of LRRK2-KO phenotypes are reproduced
in kinase dead LRRK2 knock-in mice or mice exposed to kinase
inhibitors, but not in kidneys from homozygous G2019S knock-
in mice (29).
Collectively, these observations suggest that LRRK2-KO kid-
neys can be used to investigate the normal function of this pro-
tein. Here, we performed two proteomic screens comparing
LRRK2 deficient or LRRK2 G2019S knock-in mouse kidneys with
age-matched controls to address endogenous LRRK2 function
in vivo. Our findings demonstrate that, first, LRRK2 deficiency
results in proteome changes showing enrichment in proteins
involved in cytoskeletal stability, lysosomal degradation and
protein translation and, secondly, that the G2019S mutant does
not mimic the KO state. Therefore, loss of LRRK2 influences
multiple cellular pathways in a co-ordinated manner and
G2019S does not result in overlapping proteomic changes.
Results
Differentially expressed vesicular trafficking and protein
translation proteins in LRRK2-KO kidneys
To survey proteomic differences between LRRK2-KO mice and
WT littermate controls, we performed iTRAQ with ultracentrifu-
gated fractions, a 10K supernatant enriched in cytosolic proteins
and a 10K pellet enriched in microsomal proteins. This
fractionation step was performed with the intent to reduce sam-
ple complexity and improve peptide coverage in our iTRAQ
screen. We focused on changes in protein abundance as a mea-
sure of differential expression to provide an unbiased and quan-
titative insight into physiological processes such as protein
synthesis and degradation potentially affected by LRRK2.
We compared each fraction from each animal against a com-
mon reference pool, with both genotypes distributed across dif-
ferent iTRAQ runs (Fig. 1A). To confirm sample enrichment, we
performed immunoblots to detect the abundance of specific pro-
tein markers for each fraction. As expected, late-endosome and
lysosome markers, the small GTPase Rab7 and the membrane
protein LAMP1, were significantly enriched in the 10K pellets
compared with the 10K supernatants (Fig. 1B), although Rab7
was also detected in 10K supernatants. In addition, the cytosolic
protein GAPDH was enriched in the 10K supernatant (Fig. 1B). As
the goal of this enrichment was to improve protein detection
rather than the generation of more defined pure fractions, these
samples were used for the following proteomic experiments.
In the 10K supernatants samples, we identified 700 (Run 1)
and 600 (Run 2) unique proteins, with 504 common proteins. In
the 10K pellets, 1500 (Run 1) and 1800 (Run 2) unique proteins
were detected, with 1187 shared hits. Totally, 375 of the proteins
were detected in both fractions. In the 10K supernatants, 23 pro-
teins differed significantly in abundance between LRRK2-KO
and controls, with most proteins showing higher detection in
the KO animals compared with WT (Fig. 1C). We further identi-
fied 25 significantly different proteins in the 10K pellets, of
which 5 were also significantly different in the 10K superna-
tants (Fig. 1D). Unsupervised hierarchical clustering of differen-
tial proteins separated genotypes in both 10K supernatants and
10K pellets (Fig. 1E and F). We classified differentially abundant
proteins using gene ontogeny (GO) analysis (Fig. 2). Consistent
with previous findings (18), we found significant enrichment in
categories related to protein degradation (Fig. 2), including the
GO: cellular compartment terms lytic vacuole and lysosomal lu-
men (Fig. 2; Supplementary Material, Fig. S1B). These categories
were populated by multiple lysosomal enzymes including ca-
thepsin D (Ctsd), legumain (Lgmn), dipeptidyl peptidase 7
(Dpp7) and galactosidase beta 1 (Glb1), all found in higher abun-
dance in LRRK2-KO compared with WT mice (Fig. 1C and D).
Cytoskeletal proteins were also differentially expressed in KO
kidneys. Lower levels of Tubb4b and gephyrin (Gphn) were noted
in LRRK2-KO 10K pellets (Fig. 1D and F), while coronin 1C (Coro1c),
protein kinase C and casein kinase substrate in neurons protein 1
(Pacsin2) and septin 9 (Sept9), were significantly higher in the
LRRK2-KO 10K supernatants compared with controls (Fig. 1C
and E). Many of these proteins were also represented in the
GO: Cellular compartment term ‘extracellular exosome’
(P¼ 3.131012 (Fig. 2; Supplementary Material, Fig. S1B).
A third set of proteins related to ‘initiation of mRNA and pro-
tein translation’ was differentially abundant in LRRK2-KO 10K
pellets (Fig. 2; Supplementary Material, Fig. S1D). Among these,
heterogeneous nuclear ribonucleoprotein K (Hnrnpk) and elon-
gation factor 1-gamma (Eef1g) were higher in the 10K superna-
tants of KO animals compared with controls, while the
eukaryotic translation initiation factor 4 subunit G3 (Eif4g3) and
related proteins Eif5, Eif3l were lower in KO 10K pellets.
In summary, we found clear significant differences in abun-
dance of proteins functioning in synthesis and catabolic
function. Most of these proteins belonged to three main catego-
ries, proteins important for protein translation, cytoskeletal
function and lysosomal function.
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G2019S knock-in mutant kidneys do not show detect-
able differences in protein expression levels
Collectively, the above data nominate a series of proteins that
respond to LRRK2 deficiency in vivo. To address effects of a PD
associated Lrrk2 mutation, we performed a second iTRAQ exper-
iment using LRRK2-G2019S knock-in animals. We identified 729
unique proteins in the 10K supernatants (Fig. 3A) and 785
unique proteins in the 10K pellets (Fig. 3B). However, we did not
detect any significant differences in protein abundance between
genotypes in either fraction (Fig. 3A and B). Given that the num-
ber of proteins detected in each experiment varied and that
iTRAQ ratios have a compressed dynamic range (33), we
were concerned that the apparent negative result in the G2019S
experiment was owing to an underestimate of true
differences. We therefore directly compared the KO and G2019S
Figure 1. Proteomic analysis of LRRK2 KO kidneys. (A) Tables of the iTRAQ runs: 10K supernatants and 10K pellets for two independent experiments. Schematic experi-
mental plan including sample preparation, representative iTRAQ labeling, peptide fractionation via LC followed by tandem MS. (B) Immunoblots from kidney enriched
fractions for endo-lysosomal markers Rab7 and LAMP1, and for the cytosolic marker GAPDH (n¼4). Volcano plots of the 504 proteins quantified in the 10K supernatants
(C) and of the 1187 proteins quantified in the 10K pellets (D) (n¼5, Welch T-test, P values corrected using Benjamini–Hochberg post hoc test). Heat maps of significant
genes differently regulated in 10K supernatants (E) and 10K pellets (F). WT, wild-type; KO, LRRK2-KO; S, 10K supernatant; P, 10K pellet.
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experiments for those proteins detected in all experiments for
each fraction. Using hierarchical clustering, we found that the
KO samples separated from both G2019S knock-in and WT sam-
ples but knock-in and WT did not (Fig. 3C and D). No correlation
was found between LRRK2-G2019S knock-in protein abundance
in comparison to WT for 10K supernatants (Fig. 3E; Pearson’s
correlation between log2-fold differences, R¼ 0.0496, P¼ 0.389,
n¼ 304 proteins) or pellets (Fig. 3F; Pearson’s correlation be-
tween log2-fold differences, R ¼-0.0445, P¼ 0.308, n¼ 527
proteins).
We considered whether the lack of effect of the G2019S ge-
notype might result from temporal separation of experiments.
To address this, we re-ran KO 10K supernatants against WT
controls as in the first iTRAQ experiment. Again, we saw similar,
significant differences in genotype (Supplementary Material,
Fig. S2A) sufficient to separate genotypes using hierarchical
clustering (Supplementary Material, Fig. S2B). Moreover, there
was a positive correlation between the Log2 ratios of KO to WT
proteins in the two runs (Supplementary Material, Fig. S2C) but
again not with the G2019S knock-in proteins (Supplementary
Material, Fig. S2D). Overall, these results show that the G2019S
allele has no distinguishable effect on the proteome compared
with the strong effect on protein abundance observed upon
Lrrk2 KO under the used experimental conditions.
Validation of iTRAQ results confirms deregulation of
proteins important for translational, lysosomal and
cytoskeletal function
To validate these results, immunoblots were performed for can-
didate proteins using the same protein extracts from the initial
12-month-old cohort of animals (n¼ 5 per group) and G2019S
knock-in animals for direct comparison to LRRK2-KO kidneys
(Fig. 4A–E). We first confirmed the expected absence of LRRK2 in
both LRRK2-KO enriched fractions (Fig. 4A and B). In our proteo-
mic analysis, cathepsin D was significantly higher in the LRRK2-
KO 10K supernatants compared with controls. Immunoblot
results confirmed higher levels for both mature [P¼ 0.0001,
Bonferroni post hoc test from one-way analysis of variance
(ANOVA), n¼ 5 animals] and precursor (P¼ 0.0004) forms of ca-
thepsin D in LRRK2-KO (Fig. 4A and C). There were no differen-
ces between WT and LRRK2-G2019S for cathepsin D (Fig. 4A and
C). Similarly, higher levels of the lysosomal protease legumain
were confirmed in both fractions by immunoblot (P< 0.0001;
Fig. 4A and C). Legumain was not detected in the G2019S iTRAQ
screen, but immunoblot of the LRRK2-G2019S enriched fractions
did not detect any difference in legumain expression compared
with controls (Fig. 4A, C and D). Cathepsin D mature (P¼ 0.0006)
and precursor forms (P¼ 0.0014) were also higher in the LRRK2-
KO, but not in LRRK2-G2019S, 10K pellets compared with WT
controls (Fig. 4B and D). Legumain was nominated as increased
in LRRK2-KO 10K pellets by iTRAQ (P adjusted ¼0.049), which
was confirmed using immunoblotting in KO samples (P< 0.05)
but not in G2019S knock-in samples (Fig. 4B and D).
Our iTRAQ results indicated that NatA Auxiliary Subunit
15 (Naa15), a protein important for co-translational protein
acetylation that may also interact with the cytoskeleton (34),
was lower in LRRK2-KO 10K pellets and higher in LRRK2-KO 10K
supernatants compared with controls (Fig. 1B and C). We con-
firmed lower protein levels of Naa15 in 10K pellets (P¼ 0.0003)
(Fig. 4B and D) but found that Naa15 expression was also
lower in 10K supernatants (P¼ 0.011) (Fig. 4A and C). Naa15 pro-
tein expression was significantly increased in G2019S 10K
Figure 2. Altered gene ontology pathways in LRRK2 KO kidneys. Map of dysregulated gene ontology pathways was generated using the Enrichment map Cytoscape
plug-in. Analysis was performed with gProfileR package using a false discovery rate correction. Cellular component (CC), biological process and molecular function
have been depicted for each gene set. Node size corresponds to the number of genes in each GO term. Only GO terms ranging between 10 and 5000 were included in
this analysis. Node color corresponds to which gene set each enrichment is derived from with shading being proportional to P value (cutoff, 0.05). Edges signify signif-
icant overlap between GO terms using a cutoff of 0.5 similarity coefficient, darker edges indicate greater overlap between terms.
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supernatants, compared with LRRK2-KO or WT samples
(P< 0.0001) (Fig. 4A and C). Two additional proteins with impor-
tance for protein translation, elongation factor 1-gamma (Eef1g)
and heterogeneous nuclear ribonucleoprotein K (Hnrnpk), both
showed a significant increase in LRRK2-KO but no change in
G2019S knock-in tissue (Fig. 4A and C).
We next examined a series of cytoskeleton-associated pro-
teins. The actin binding protein coronin 1C (Coro1c) was
detected as more abundant in LRRK2-KO mice compared with
controls in our iTRAQ experiments. A 53 kDa band correspond-
ing to coronin 1C was decreases in the LRRK2-KO kidneys but a
lower molecular weight band (37 kDa) was significantly in-
creased by LRRK2 deficiency (P< 0.001) (Fig. 3A and D). We there-
fore infer that the lower band is likely to correspond to the
unique peptide detected as increased in the iTRAQ dataset. The
microtubule-associated protein gephyrin (Gphn), significantly
Figure 3. Proteomic analysis of LRRK2 G2019S knock-in kidneys. Volcano plots of the 729 proteins quantified in the 10K supernatants (A) and of the 785 proteins quanti-
fied in the 10K pellets (B) (n¼5, Welch T-test, P values corrected using Benjamini–Hochberg post hoc test). Heat maps of detected genes (with P value <0.05 before cor-
rection) in 10K supernatants (C) and 10K pellets (D). Correlation of fold-changes between G2019S-KI and LRRK2-KO, in 10K supernatants (E) and 10K pellets (F).
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decreased in LRRK2-KO 10K pellets in iTRAQ, was validated in
10K supernatants (P< 0.0001) and pellets (P¼ 0.0025) (Fig. 4A–D).
To address the observed changes in tubulin associated proteins
including Tubb4b further and given the lack of specific reliable
anti-Tubb4b antibodies, we investigated differences in total and
acetylated tubulin in our samples. A significant increase in
acetylated-tubulin adjusted to a/b-tubulin was detected in 10K
supernatants from KO animals compared with WT (P¼ 0.0171).
Additionally, a/b-tubulin, normalized expression levels were
significantly lower in LRRK2-KO 10K supernatants compared
with controls (P¼ 0.0002) (Fig. 4A–D). No significant difference in
gephyrin, acetylated or total tubulin was detected between
G2019S and WT animals.
To investigate whether changes could be observed in
neural tissue, immunoblots were performed on cerebral cortex,
hippocampus and striatum from the same 12-month-old mice.
No significant difference was detectable between LRRK2-KO and
WT mice for most of the proteins tested (Supplementary
Material, Fig. S3) with the exception of gephyrin, where expres-
sion levels were lower in LRRK2-KO hippocampus (P< 0.05, t-
test, n¼ 5 animals) but no difference was shown in other brain
regions tested (Supplementary Material, Fig. S3E and F).
Therefore, the effects of LRRK2 deficiency on protein expression
levels in the brain are more modest than those in the kidney.
These results validate 11 out of the 12 nominated protein ex-
pression differences between LRRK2-KO and WT kidneys, with
the exception being Naa15 in the 10K supernatants. Overall, we
found that fold differences between genotypes were larger us-
ing immunoblotting than with iTRAQ (Fig. 4E), consistent
with the issue of ratio compression in iTRAQ experiments (33).
Figure 4. Validation of iTRAQ proteomics results. (A) Immunoblots for LRRK2 and the iTRAQ hits of interest normalized for the loading control b-actin in the 10K super-
natants and in the 10K pellets (B). Quantifications of immunoblots from cytsolic (C) and microsomal (D) enriched fractions. (E) Comparison of the log2-fold expression
(KO/WT) using the iTRAQ data compared with the immunoblot data.
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We did not detect differences between WT and G2019S knock-in
animals apart from Naa15, which was more abundant in the
10K supernatants, in contrast to KO lysates.
Additional biological validation reveals age-dependent
changes in LRRK2-KO kidneys
Alterations in LRRK2-KO kidneys show age-dependent effects
(18). To test whether this was true for all candidate proteins we
examined a series of independent cohorts of LRRK2-KO animals
at different ages. Given that we were able to detect our proteins
of interest by immunoblot without enrichment and we did
not observe significant protein migration between enriched
fractions, we performed immunoblots on total kidney homoge-
nates to avoid any possible protein loss.
No significant differences were observed in kidney lysates
from LRRK2-KO and control newborn (P0) mice (n¼ 6 animals
per genotype) in any of the markers examined except for a sig-
nificant decrease in Hnrnpk levels in LRRK2-KO kidneys (Fig. 5A
and F; Supplementary Material, Fig. S4). In 1-month-old animals
(n¼ 6), we observed a small but significant accumulation of the
mature form of cathepsin D, an equally small but significant in-
crease in Hnrnpk and decrease in Eef1g, and significantly lower
Figure 5. Biological validation of iTRAQ results across aging cohorts. Immunoblots for the iTRAQ proteins of interest using kidney homogenates from P0 (A), 1-month-
old (B), 9-month-old (C), 12-month-old (D) LRRK2-KO and control mice. Plots indicating the differences in the iTRAQ candidate lysosomal hydrolases (E), translational
regulators (F) and cytoskeletal-associated proteins (G) quantified from the immunoblots, between aging cohorts (Supplementary figure for additional immunoblot
quantification graphs).
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levels of a/b-tubulin and a substantial increase in acetylated-
tubulin in KO animals compared with WT. No changes were
detected for legumain, Naa15, coronin 1C, gephyrin (Fig. 5B;
Supplementary Material, Fig. S4).
In an independent cohort of 9-month-old mice (n¼ 3), ca-
thepsin D and legumain levels were significantly higher in
LRRK2-KO kidney homogenates compared with WT animals.
Naa15 protein levels were significantly decreased in the LRRK2-
KO samples and a similar level of coronin 1C was noted as seen
in the initial cohort used for proteomics. We also detected sig-
nificantly lower levels of a/b-tubulin, together with higher levels
of tubulin-acetylation (Fig. 5C; Supplementary Material, Fig. S4).
We also confirmed similar differences in kidney homogenates
from the 12-month-old mouse cohort (n¼ 5) used for iTRAQ
experiments (Figs 4 and 5D; Supplementary Material, Fig. S4).
Collectively, these results show that an increase in lysosomal
proteases together with a decrease in total tubulin accompanied
by an increase in tubulin acetylation are detectable throughout
most of the time points and therefore are the most consistent.
Changes in translational proteins were found to be the least con-
sistent over time. Of the nominated differences between geno-
types, at the earliest ages there were changes in Hnrnpk and
Eef1g, accumulation of mature cathepsin D, and loss of a/b-tubu-
lin accompanied by an increase in acetylated tubulin. These
results suggest that the primary responses to LRRK2 deficiency in
the kidney include translational, lysosomal and cytoskeletal
changes but that changes over time affect more consistently in
particular lysosomal hydrolases and cytoskeletal proteins.
Accumulation of endo-lysosomal clusters in
LRRK2-KO kidneys
To further characterize the LRRK2-KO lysosomal phenotype, we
performed immunofluorescent staining of kidney sections from
6-month-old animals. As expected, LRRK2-KO kidneys were
larger, heavier and darker in color than their WT counterparts
(Supplementary Material, Fig. S5A and B). The most prominent
observed changes were enlarged and more numerous cathepsin
D positive punctae in the proximal tubules of LRRK2-KO kidneys
(Fig. 6A, F, G). To better discern cathepsin D positive vesicles, we
used super-resolution microscopy (Fig. 6B). Cathepsin D par-
tially colocalized with the late-endosomal/lysosomal marker
LAMP1 in WT animals but showed more distinct localization to
the lysosomal membrane in KO animals (Fig. 6B). LAMP1 posi-
tive structures appeared also significantly enlarged in LRRK2-
KO (Fig. 6A and H). Analysis of cathepsin D and LAMP1 show an
increase in colocalization between the two markers in LRRK2-
KO kidneys indicating an accumulation of cathepesin D in the
endo-lysosomal compartment (Fig. 6D).
Lysosomal proteases such as cathepsin D are synthesized in
the ER as inactive precursors, recognized by mannose-6-
phosphate receptor (M6PR) and transported via the trans-Golgi
network and sorting endosomes to lysosomes where they un-
dergo maturation by pH-dependent proteolytic cleavage (35).
We hypothesized that LRRK2 deficiency affects cathepsin D pro-
tein sorting via its receptor. To test this hypothesis, we analyzed
cathepsin D and cation-independent M6PR (CI-M6PR) by immu-
nofluorescence in kidney sections (Fig. 6C). We observed an in-
crease in colocalization between cathepsin D and CI-M6PR in
LRRK2-KO kidneys (Fig. 6E) suggesting a scenario in which ca-
thepsin D and its receptor are accumulating in an endo-
lysosomal compartment and fail to recycle back to the Golgi.
To further investigate this hypothesis, we probed 12-month-old
kidney extracts for LAMP1 and M6PR by immunoblot. We ob-
served a significant increase in M6PR in LRRK2-KO kidney
extracts (Fig. 6I and J). Surprisingly, no significant differences in
LAMP1 levels were detected although we can observe an in-
creasing trend in the KO (Fig. 6I and K). Taken together, these
results suggest that cathepsin D trafficking is dysregulated in
LRRK2 KO kidneys.
Primary kidney cells show that lysosomal dysregulation
is a primary consequence of LRRK2 deficiency
To investigate the possibility of dysregulated cathepsin D traf-
ficking further and gain more in depth inside into the most re-
producible and earliest increase in protein abundance observed
in our animal cohorts, we cultured epithelial cells from the kid-
ney cortex from WT and LRRK2-KO animals.
As in vivo, cells lacking LRRK2 had fewer but larger cathepsin
D positive clusters compared with WT controls, resulting in an
overall accumulation of cathepsin D (Fig. 7A–D). We did not de-
tect a significant difference in LAMP1 fluorescence intensity
(Supplementary Material, Fig. S7). This is in contrast to what
was observed in kidney histological sections in LRRK2-KO
(Fig. 6). The lack of a significant increase in LAMP1 between gen-
otypes in cells is in accordance with cathepsin D increase in
precursor but not in the mature form (Fig. 7C). To further inves-
tigate this difference we measured the colocalization of cathep-
sin D with LAMP1 in primary kidney cells (Supplementary
Material, Fig. S7). Here, we observed a decrease in colocalization
between the two markers in LRRK2-KO cells. These data suggest
that in our cell model the lysosomal hydrolase cathepsin D is
improperly processed and accumulates in pre-lysosomal
compartments.
In our attempt to provide a mechanistic explanation for
this accumulation, we next asked whether we could observe
the same differences in the CI-M6PR trafficking pathway
reported in kidney sections (Fig. 6C). We observed enlarged,
and more dispersed CI-M6PR-positive vesicles in primary
LRRK2-KO cells compared with WT cells (Fig. 7E and F) suggest-
ing that defects in vesicle trafficking may be important
in LRRK2 effects on lysosomal proteases. To further test this
hypothesis, we inhibited lysosomal acidification using
bafilomycin-A1 (Supplementary Material, Fig. S6A and B). As
expected, mature cathepsin D levels were decreased in re-
sponse to bafilomycin-A1, whereas we observed a decrease in
the precursor form of cathepsin D and increase of pre-pro ca-
thepsin D together with an increase in LC3-II. Interestingly,
the differences between genotypes were abolished upon bafi-
lomycin treatment, suggesting that trafficking rather than ex-
pression of cathepsin D is the critical regulator of cathepsin D
levels (Supplementary Material, Fig. S6A and B). Supporting
this idea, we further confirmed that cathepsin D mRNA ex-
pression does not differ between genotypes (Supplementary
Material, Fig. S6C–G). Another possible interpretation of the
results obtained after bafilomycin treatment is that we could
observe an increase in cathepsin D secretion, previously
reported upon treatment with this lysosomal inhibitor (36).
Defects in cathepsin D trafficking have been reported in cells
expressing the dominant negative form of Rab7 (37) showing a
collapse of the endosomal system typified by swollen endo-
somes positive for both endosomal and lysosomal markers.
To test whether the defective trafficking of cathepsin D in
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LRRK2-KO cells is also coupled with defective endo-lysosomal
organization we quantified colocalization between cathepsin D
and the early endosomal localized CI-M6PR (Fig. 7G and H). As
expected in wild-type cells the two proteins showed partial
colocalization onto small (500 nm to 1 lm) punctate endosomes.
However, in LRRK2-KO cells we observed a significant increase
in the colocalization between the two markers indicating a fun-
damental defect in the organization of the endo-lysosomal sys-
tem. Therefore, in both kidney cells and tissue we observed an
increase in colocalization between cathepsin D and the CI-M6PR
suggesting impaired receptor recycling in the absence of LRRK2.
These results show that deficiencies in the organization of the
endo-lysosomal system represent a primary event in response
to loss of LRRK2.
Discussion
Understanding the physiological function of LRRK2 has implica-
tions for nominating biological processes relevant to PD and
may be important for predicting safety and tolerability of LRRK2
Figure 6. Histological characterization of LRRK2 KO kidneys. (A) Confocal imaging of WT, LRRK2-KO (5- to 6-month-old, n¼3) for cathepsin D (rabbit polyclonal anti-
body, AlexaFluor 568 secondary antibody), LAMP1 (rat monoclonal antibody, AlexaFluor 488 secondary antibody) and DAPI staining. Scale bar: 20 lm. (B)
Representative Airy scan images of the same WT and LRRK2-KO kidneys for cathepsin D, LAMP1 and DAPI staining. Scale bar: 10 lm. (C) Confocal imaging of the same
WT and LRRK2-KO kidneys for cathepsin D (goat polyclonal antibody, AlexaFluor 568 secondary antibody) and M6PR (rabbit monoclonal antibody, AlexaFluor 488 sec-
ondary antibody) and DAPI staining. Scale bar: 20 lm. (D) Quantification of cathepsin D and LAMP1 colocalization in the kidney sections shown in panel (A). (E)
Quantification of cathepsin D and M6PR colocalization in the kidney sections shown in (C). Data points represent Pearson’s correlation coefficient from at least five
images per animal, with multiple cells per image, n¼3 mice per genotype. (F) Number of cathepsin D punctae per nuclei and area (lm2) of cathepsin D (G) and LAMP1
(H) positive vesicles. (I) Immunoblot analysis of WT and LRRK2-KO kidney lysates (12-month-old total homogenates, n¼5) using CI-M6PR and LAMP1 antibodies.
Quantifications of CI-M6PR (J) and of LAMP1 (K) immunoblots normalized for the loading control b-actin.
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kinase inhibitors if these compounds proceed to clinical trials.
Here, we show that genetic ablation of LRRK2 is associated with
altered levels of proteins related to lysosomal, cytoskeletal and
protein translation pathways in vivo. In cells, we find enhanced
trafficking of the CI-M6PR to lysosomes, potentially identifying
a very early consequence of LRRK2 inhibition resulting in the
observed accumulation of lysosomal proteases over time. In
contrast, mice harboring the G2019S allele do not display any
overt phenotypic difference from control mice and show only
minimal changes in protein expression compared with the clear
changes in LRRK2-KO mouse kidneys. Our observations show-
ing no clear effects on protein abundance argue against a simple
Figure 7. Impaired trafficking of mannose-6-phosphate receptor in LRRK2 KO cells. (A) Cellomics representative images of WT and LRRK2-KO primary kidney cells.
(B) Quantifications of percentage of cells with cathepsin D structures, average spot area (lm2) and average intensity counted using the spot detector bioapplication of
the Cellomics arrayscan. (C) Immunoblots for cathepsin D in total homogenates from LRRK2-KO and control primary kidney cells. (D) Immunoblot quantifications of
cathepsin D precursor and mature forms. (E) Representative confocal images of LRRK2-KO and wild-type primary kidney cells stained in red for cathepsin D (anti-rab-
bit, AlexaFluor 568 secondary antibody), in green for M6PR (anti-mouse, Alexa 488 secondary antibody). Nuclei in blue were stained with Hoechst. Scale bar¼20 lm
(5 lm for magnification). (F) Quantifications of percentage per cell, average area and average intensity of M6PR punctae in LRRK2-KO and wild-type primary kidney
cells. (G) Pearson’s correlation coefficient measured by manually quantifying 50 cells after confocal imaging and (H) overlap area (lm2) measured by high content image
analysis.
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dominant negative mechanism for the G2019S mutation in PD
kidneys and/or brain.
Prior studies of LRRK2-KO mice have identified multiple ab-
normalities in kidneys (30,32,38). Here, we have extended past
approaches to show more defined alterations in multiple lyso-
somal proteases, cytoskeletal proteins and protein translational
components. Changes in the latter two protein categories are
consistent with the reported biology of LRRK2. For example,
LRRK2 was shown to bind tubulin directly (21), influence actin
dynamics (39) and may regulate phosphorylation of the micro-
tubule binding protein tau (40–45). Similarly, overexpression of
proteins that regulate translation, including 4EBP1 (25,46) and
RPS15 (47), can mitigate toxic effects of mutant LRRK2. Overall,
the broad range of proteins that are differentially regulated in
our proteomics analysis suggests that endogenous LRRK2
affects multiple proteins in three major categories.
This study suggests that loss of Lrrk2 influences lysosomal,
cytoskeletal and protein translation and that defective intracel-
lular protein trafficking is the primary cause. We were able to
show that localization of CI-M6PR is altered in LRRK2-KO cells,
suggesting inherent alterations in trafficking in these cells.
Interestingly, we find greater colocalization between CI-M6PR
and cathepsin D. This could indicate either that cells are in-
creasing the rate of trafficking to the lysosome or are failing to
recycle CI-M6PR after delivery. As LRRK2 phosphorylates multi-
ple members of the Rab family of small GTPases (48–50) one po-
tential testable hypothesis that emerges from these
observations is that KO cells and tissues upregulate protein traf-
ficking pathways to compensate for loss of Lrrk2-dependent Rab
phosphorylation (51,52). It is also possible that the role of LRRK2
in the membrane trafficking pathways here studied is not medi-
ated simply by its kinase activity but by other functional protein
interaction domains such as the GTPase Roc-COR domain which
seems involved in retrograde trafficking via downstream Rab
GTPases such as Rab29 (53). In addition, LRRK2 could play a
scaffolding role along microtubules, helping the formation of
signaling complexes involved in membrane trafficking (21).
The distinction between specific regulation of individual
proteins and broad alterations in categories of biologically re-
lated molecules is important as it suggests some of the observed
changes may be compensatory responses to loss of Lrrk2.
Supporting this interpretation, our data shows that differences
between genotypes increase slowly over several months then
tend to diminish partially with age, consistent with prior data
suggesting complex biphasic responses with aging in LRRK2-KO
animals (18). We therefore propose that Lrrk2 is involved in mul-
tiple cellular pathways and that, to compensate for lack of Lrrk2,
there are compensatory and co-ordinated responses in the
same pathways.
The relevance of this detailed study in brain and kidneys in
loss of function and gain of kinase function models lies first in
the identification of novel categories of proteins affected by loss
of Lrrk2. These findings lay emphasis on the concept that kinase
inhibitors might affect several intracellular pathways accumu-
latively over time. Second, the lack of concordance in proteomic
changes between LRRK2-KO and the G2019S knock-in animals
supports prior data that the mutations in Lrrk2 are pathogenic
owing to gain of function rather than having dominant negative
effects.
Overall, the current data shed light on multiple protein net-
works affected by loss of LRRK2 in early stages of mouse devel-
opment and demonstrates the utility of unbiased approaches to
explore in vivo effects of gene manipulation.
Materials and Methods
Animals
Experiments using animals were conducted in compliance with
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The specific experiments per-
formed in this study were approved by the Institutional Animal
Care and Use Committees of the US National Institute on Aging
(Animal study protocol number 463-LNG-2018). Animal experi-
ments performed at UCL were approved by the UCL Ethics
Committee and by the home office as detailed in the relevant
project license 80/2486 (KH).
LRRK2-KO mice (54) were generously provided by Huaibin
Cai, NIA. LRRK2 G2019S knock-in mice were generated as de-
scribed previously (55). For proteomics experiments and for vali-
dation by western blotting, age-matched WT, homozygous
LRRK2-KO mice and heterozygous knock-in mice, each bred on
a C57BL/6J background, were euthanized by cervical dislocation.
For additional biological validation of the effects of age on pro-
tein expression, we generated separate cohorts of WT and
LRRK2-KO mice. From each animal, one kidney was immedi-
ately frozen in dry ice while the other was fixed in 4% PFA in
PBS for histological analysis. Brain hemispheres were separated
and cortex, striatum and hippocampus were dissected and fro-
zen in dry ice.
Kidney sample preparation
For iTRAQ proteomic experiments, frozen kidneys dissected
from 1-year-old mice were homogenized using Dounce homog-
enizers in isolation buffer containing 0.225 M mannitol, 0.05 M
sucrose, 0.0005 M HEPES, 1 mM EDTA. The homogenate was
centrifuged at 2000g for 3 min at 4C and the supernatant then
collected in a separate tube and centrifuged at 12 000g for
8 min at 4C. The supernatant was then centrifuged at
100 000g for 30 min at 4C and the resulting 10K supernatant
and pellet fractions retained. The 10K pellets were resuspended
in iTRAQ compatible buffer (0.3 M HEPES, 2% CHAPS, 1 mM
EDTA). Total kidney homogenates for immunoblot validation of
additional cohorts were prepared in lysis buffer (20 mM Tris–
HCl, 1% NP40, 150 mM NaCl, 1 mM EDTA, 10% glycerol), with
protease inhibitor cocktail tablet (Roche) and Halt phosphatase
inhibitor (ThermoScientific) added immediately before use.
Protein concentrations were determined using 660 nm protein
assay reagent (Pierce) using bovine serum albumin as a stan-
dard reference.
Primary kidney cells preparation
For primary kidney cell preparation, kidneys from 8- to
9-month-old mice were collected and washed in cold HBSS
(Hank Balances Salt Solution, Gibco) to remove residual blood.
Renal fibrous capsule, connective tissue and renal medulla were
removed. Kidney cortical tissue was dissected and mechanically
minced using scalpels. Tissue homogenates were then trans-
ferred into 50 ml falcon tubes containing HBSS with 1 mg/ml
Collagenase IV (Invitrogen) to allow digestion at 37C for 30 min.
Digested kidney fragments were then passed through a 100 lm
sieve in another falcon tube to remove fibrous tissue. The sieve
was washed in HBSS and the cell suspension centrifuged at
1200 rpm for 5 min two times. Finally, the cell pellet was resus-
pended in complete culture media: DMEM/F12 1:1 media
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(Invitrogen) containing 5% FBS, 10 ng/ml epidermal growth fac-
tor (Invitrogen), 1% penicillin/streptomycin (Invitrogen), 1% L-
glutamine (Invitrogen), 50 mM hydrocortisone (Sigma Aldrich),
5 lg/ml insulin (Invitrogen), 5 lg/ml transferrin (Sigma Aldrich)
and 50 nM sodium selenite (Sigma Aldrich). Cells were cultured
in 75 cm2 plastic flasks with complete culture medium at 37C
under 5% CO2 in a humidified atmosphere.
Isobaric tag for relative and absolute quantitation
(iTRAQ) labeling
For iTRAQ experiments, we modified procedures we previously
reported for mouse brain samples (56). Kidney 10K supernatants
and pellets from five WT and five LRRK2-KO samples were ana-
lyzed in two separate experiments for a total of four iTRAQ runs
(Fig. 1). A pooled reference sample was made by combining
40 lg of each of the WT samples together. The concentration of
each sample was adjusted to 1 lg/ll with iTRAQ buffer (0.3 M
HEPES, 2% CHAPS, 1 mM EDTA). Samples were treated with 2 ll
of tris(2-carboxyethyl)phosphine for 60 min at 60C and subse-
quently alkylated with 1 ll of methyl methanethiosulfonate for
20 min at RT. The mass spectrometry grade trypsin (Promega)
was used to digest the samples. The first digestion was carried
out overnight at 37C with a trypsin:protein ratio of 1:100 (w/w).
The samples were digested again with a trypsin:protein ratio of
1:100 (w/w) for 8 h at 37C. Before addition to samples, iTRAQ
eight-plex reagents were dissolved in 150 ll of isopropanol and
vortexed. Each sample mixture was then labeled for 3 h at RT
with the appropriate iTRAQ reagent, and labeled peptide mix-
tures were combined. Samples were desalted using an Oasis
HLB 200 mg cartridge. Fractionation of iTRAQ labeled peptides
by liquid chromatography (LC) and subsequent tandem mass
spectrometry (MS/MS) analyses of the fractions were performed
as previously described (56).
Western blotting
Equal amounts of total protein from each preparation were sepa-
rated using SDS-PAGE and transferred into nitrocellulose mem-
branes. After 1 h blocking with Odyssey Blocking Buffer (LI-COR),
membranes were probed overnight with primary antibodies (listed
in the following section). Incubation with IRDye-labeled 800CW
goat anti-rabbit and goat anti-mouse secondary antibodies (LI-
COR, 1:15 000) was performed for 1 h at RT. Protein bands of inter-
est were visualized with Odyssey CLx Infrared Imaging Studio.
Band intensity was quantified using LI-COR Image Studio software.
Antibodies
The following antibodies used for immunoblot were diluted in a
1:1 mix of Odyssey Blocking Buffer (LI-COR) and TBS containing
0.1% (v/v) Tween 20:rabbit polyclonal antibody to cathepsin D
(Millipore, 219361, 1:1000), goat polyclonal antibody to cathepsin
D C-20 (Santa Cruz, sc-6486, 1:200), rabbit polyclonal antibody to
legumain (Abcam, ab125286, 1:1000), mouse monoclonal anti-
body to gephyrin (Synaptic System, 147 111, 1:2000), mouse
monoclonal antibody to b-actin (Sigma, A5316, 1:10 000), rabbit
polyclonal antibody to a/b-tubulin (Cell Signaling, 2148, 1:1000),
mouse monoclonal antibody to acetylated-tubulin (Sigma,
T7451, 1:1000), rabbit polyclonal antibody to coronin 1C
(Proteintech, 14749-1-AP, 1:1000), mouse monoclonal antibody
to NAA15 (LSBio, LS-C342562, 1:1000), rabbit polyclonal to EEF1G
(Abcam, ab72368, 1:1000), mouse monoclonal to HNRNPK
antibody (Abcam, ab23644, 1:1000) and rabbit polyclonal to LC3B
(Abcam, ab51520, 1:2000). The following antibodies were used
for immunohistochemistry: rabbit polyclonal antibody to ca-
thepsin D (Millipore, 219361, 1:200), goat polyclonal antibody to
cathepsin D C-20 (Santa Cruz, sc-6486, 1:200), rat monoclonal
antibody to LAMP1 (1D4B) (Abcam, ab25245, 1:200), mouse
monoclonal to mannose-6-phosphate receptor cation indepen-
dent (CI-M6PR) antibody [2G11] (Abcam, ab2733, 1:200), rabbit
monoclonal to CI-M6PR [EPR6599] (Abcam, ab124767, 1:200).
Histological analysis
Kidneys were fixed post-mortem by immersion in 4% PFA over-
night and then transferred to PBS with 30% sucrose and 0.05%
sodium azide for 24 h. Tissues were then frozen and 40 lm sec-
tions cut using a Leica CM1900 cryostat. After three 5 min
washes in PBS, sections were blocked at room temperature for
1 h in blocking buffer (0.3% Triton, 1% BSA, 1% donkey serum in
PBS). The same buffer was used for the primary antibody incu-
bation overnight at 4C with gentle shaking. Sections were then
washed 3 times in PBS for 10 min and incubated with Alexa
Fluor secondary antibodies (donkey anti-rabbit and donkey
anti-goat, 1:500) for 2 h at room temperature. After three 10 min
washes in PBS, sections were mounted on glass slides using
Prolong Gold mounting media (Life Technologies).
Immunocytochemistry
Primary kidney cells were seeded in poly-D-lysine coated cover-
slips and fixed in 4% PFA for 20 min. Cells were then incubated for
1 h with blocking buffer (0.1% Triton, 5% FBS in PBS) and the same
buffer was used for the following antibody incubations. Primary
antibody incubation was performed for 2 h at RT. Cells were then
washed three times in PBS prior to secondary antibody incubation
for 1 h with Alexa Fluor antibodies diluted 1:500. Each coverslip
was then mounted on a microscope slide using Prolong mounting
media (Sigma) and left to dry overnight at RT.
Confocal microscopy
Confocal microscopy was performed using a Zeiss LSM 710 (Carl
Zeiss). Fluorescence was excited by the 405, 488 and 595 nm la-
ser lines of Argon, diode and Helium/Neon lasers, respectively.
Images were taken with a 40 1.3 numerical aperture (NA) or
631.4 NA oil objective. Images were collected using Zen soft-
ware (Carl Zeiss) and prepared using Fiji (NIH). Representative
images are shown without any additional processing. Airyscan
imaging was performed using a Zeiss 880 outfitted with an
Airyscan module. Data were collected using a 631.4 NA objec-
tive and immersion oil optimized for 30C (Carl Zeiss). Colors
were collected sequentially to minimize crosstalk, and Airyscan
processing was performed using the Airyscan module in the
commercial ZEN software package (Carl Zeiss).
High content imaging
Cells that had been fixed and immunostained for confocal analy-
sis were subsequently analyzed using a ThermoScientific
Cellomics ArrayScan VTI HCS Reader. Plates were imaged using a
20 objective and analyzed using the Spot Detector bioapplication
for percent of cells with cathepsin D-positive spots from total
number of cells, average spot area and intensity of staining per
cell.
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Image quantification
Quantification was performed by an individual blinded to geno-
type using a combination of custom algorithms in Fiji (NIH),
Imaris (Biplane, Inc.) and in NIS Elements analysis software. To
assist the algorithm in correctly identifying the structures, back-
ground subtraction was performed by subtracting a flat numerical
value from all channels in all images. The number of cathepsin
D-positive vesicles was quantified using a spot detection algo-
rithm in Imaris, thresholds were decided from several images and
then applied to all images simultaneously. To normalize the
number of cathepsin D-positive vesicles to the number of cells in
the tissue section, the nuclei were quantified using a surface de-
tection algorithm using the method of marching squares.
Quantitative real-time polymerase chain reaction
Isolation of total RNA, reverse transcription and quantitative
real-time polymerase chain reaction (qRT-PCR) were performed
as previously described with few changes (57). Total RNA from
primary cultured mouse kidney cells and mouse kidney tissue
was isolated and purified with the RNeasy Mini Kit (QIAGEN).
RNA was reverse transcribed with the SuperScriptVR III First-
Strand Synthesis System (Invitrogen) and qPCR of diluted cDNA
was carried out on an AriaMx Realtime PCR System (Agilent
Technologies) using iTaqTM Universal SYBRVR Green Supermix
(Bio-Rad Laboratories) for a total reaction volume of 20 ml. Oligo
6.0 software (MedProbe) served as program to select intron-
spanning primers targeting the mus musculus cathepsin D gene
(NM_009983.2; 330-forward 50-GCCGCAGTGTTTCACAG-30; 479-
reverse 50-TGAGCCGTAGTGGATGTCAA-30; amplification prod-
uct: 169 bp). Optimized primers for the two housekeeping refer-
ence genes, GAPDH and b-actin, have been used as published
earlier (57): GAPDH: NM_008084; 205-forward 50-GCAAATTCAAC
GGCACA-30; 337-reverse 50-CACCAGTAGACTCCACGAC-30; am-
plification product: 141 bp; b-actin: NM_007393; forward 50-GC
CAACCGTGAAAAGATGAC-30; reverse 50-GGCGTGAGGGAGAGC
ATAG-30. In order to verify the specificity of the PCR products gel
electrophoresis, melting curve analysis and ‘-RT’ (reverse tran-
scriptase) as well as water control PCR reactions were con-
ducted. Calculation of relative expression levels for cathepsin D
in LRRK2 KO versus WT samples was determined with the DDCt
method. Statistical analysis was done using non-parametric
Mann–Whitney test.
Bioinformatics and statistical analyses
In all experiments, n represents the number of individual animals
included in an experiment. Both male and female mice were
used. Although animals were not treated and therefore not ran-
domized into treatment groups, iTRAQ proteomics experiments
were performed with animals of both genotypes included across
different proteomics runs (Fig. 1A). In all statistical analyses, a
preset value of a¼ 0.05 was used to reject the null hypothesis of
no difference, with multiple test correction as appropriate.
iTRAQ labeled peptide identification and quantitation were
performed using Mascot (58) from Xcalibur RAW files with
parameters and thresholds for peak picking as previously de-
scribed (56). Peptide identification was performed using the
Mascot Server (version 2.5) to identify homologous peptides in
the Sprot Mouse Database (Uniprot Proteome ID: UP000000589)
with iTRAQ8plex (N-term) and iTRAQ8plex (K) set as fixed modi-
fications and Methylthio (C), Oxidation (M) and iTRAQ8plex (Y)
set as variable modifications. Only unique peptides were used
to identify and calculate protein ratios. The iTRAQ label inten-
sity for each sample was divided by the intensity of the pooled
reference to obtain peptide ratios, and subsequently normalized
so that the median ratio for each peptide was 1 for the WT ani-
mals. Missing data points were imputed using k-nearest neigh-
bors in the ‘impute’ package in R within each sample type and
series only where the number of missing values was <5 (59).
Statistical inferences were assessed by Welch’s t-test, allowing
for unequal variance between groups, followed by the
Benjamini–Hochberg false-discovery rate correction for multiple
testing (60). Graphs are plotted as raw P values, but reported as
significant only if the adjusted P< 0.05. Evaluation of Gene
Ontology term enrichments was performed using gProfileR
within R (61). Protein interaction networks were acquired from
the IntAct database (http://www.ebi.ac.uk/intact/; date last
accessed July, 2016) and visualized using Cytoscape.
Data were plotted using Prism 6 (Graphpad) or R (https://
www.rstudio.com/; date last accessed July, 2016) and displayed
as means and standard error of the mean. For validation experi-
ments, Student’s t-test was used to determine differences be-
tween data consisting of two groups and ANOVA with
Bonferroni post hoc tests for multiple group comparisons.
Differences between groups were plotted on graphs using the
following codes: *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We thank Dr Huaibin Cai, NIA, for the gift of LRRK2-KO mice
and David C. Gershlick for critically reading the manuscript.
Conflict of Interest statement. None declared.
Funding
This research was supported in part by the Intramural Research
Program of the National Institute of Health, National Institute on
Aging and National Institute on Neurological Disorders and Stroke
(to M.R.C.) and the Medical Research Council [MR/M00676X/1 to
K.H.]. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Funding to pay the Open Access publication charges for this article
was provided by the Medical Research Council.
References
1. Paisa´n-Ruı´z, C., Jain, S., Evans, E.W., Gilks, W.P., Simo´n, J.,
van der Brug, M., Lo´pez de Munain, A., Aparicio, S., Gil, A.M.,
Khan, N. et al. (2004) Cloning of the gene containing muta-
tions that cause PARK8-linked Parkinson’s disease. Neuron,
44, 595–600.
2. Greggio, E. and Cookson, M.R. (2009) Leucine-rich repeat ki-
nase 2 mutations and Parkinson’s disease: three questions.
ASN Neuro, 1, AN20090007.
3. Greggio, E., Lewis, P., Van Der Brug, M.P., Ahmad, R.,
Kaganovich, A., Ding, J., Beilina, A., Baker, A.K. and Cookson,
M.R. (2007) Mutations in LRRK2/dardarin associated with
Parkinson disease are more toxic than equivalent mutations
in the homologous kinase LRRK1. J. Neurochem., 102, 93–102.
4. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M.J.,
Lincoln, S.J., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B.
3269|Human Molecular Genetics, 2018, Vol. 27, No. 1 8
et al. (2004) Mutations in LRRK2 cause autosomal-dominant
parkinsonism with pleomorphic pathology. Neuron, 44,
601–607.
5. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C.,
Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda,
A. et al. (2009) Genome-wide association study identifies
common variants at four loci as genetic risk factors for
Parkinson’s disease. Nat. Genet., 41, 1303–1307.
6. Simo´n-Sa´nchez, J., Schulte, C., Bras, J., Sharma, M., Gibbs,
J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W.,
Hernandez, D.G. et al. (2009) Genome-wide association study
reveals genetic risk underlying Parkinson’s disease. Nat.
Genet., 41, 1308–1312.
7. Nalls, M. a., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G.,
Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M. et al.
(2014) Large-scale meta-analysis of genome-wide associa-
tion data identifies six new risk loci for Parkinson’s disease.
Nat. Genet., 56, 1–7.
8. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2
(LRRK2) in Parkinson’s disease. Nat. Rev. Neurosci., 11,
791–797.
9. Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M.,
Wachter, S., Lorentzen, E., Duddy, G., Wilson, S. et al. (2016)
Phosphoproteomics reveals that Parkinson’s disease kinase
LRRK2 regulates a subset of Rab GTPases. Elife, 5, 1–28.
10. Greggio, E., Taymans, J.-M., Zhen, E.Y., Ryder, J.,
Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H.,
Baekelandt, V. et al. (2009) The Parkinson’s disease kinase
LRRK2 autophosphorylates its GTPase domain at multiple
sites. Biochem. Biophys. Res. Commun., 389, 449–454.
11. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith,
W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005)
Parkinson’s disease-associated mutations in leucine-rich re-
peat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci.
USA, 102, 16842–16847.
12. Ishihara, L., Gibson, R.A., Warren, L., Amouri, R., Lyons, K.,
Wielinski, C., Hunter, C., Swartz, J.E., Elango, R., Akkari, P.A.
et al. (2007) Screening for Lrrk2 G2019S and clinical compari-
son of Tunisian and North American Caucasian Parkinson’s
disease families. Mov. Disord., 22, 55–61.
13. Healy, D.G., Falchi, M., O’Sullivan, S.S., Bonifati, V., Durr, A.,
Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S.
et al. (2008) Phenotype, genotype, and worldwide genetic
penetrance of LRRK2-associated Parkinson’s disease: a
case-control study. Lancet. Neurol., 7, 583–590.
14. Bonifati, V. (2006) Parkinson’s disease: the LRRK2-G2019S
mutation: opening a novel era in Parkinson’s disease genet-
ics. Eur. J. Hum. Genet., 14, 1061–1062.
15. Ray, S. and Liu, M. (2012) Current understanding of LRRK2 in
Parkinson’s disease: biochemical and structural features
and inhibitor design. Future Med. Chem., 4: 1701–1713.
16. Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau,
H., Kalia, S.K., Kalia, L.V., Lobbestael, E., Chia, R., Ndukwe, K.
et al. (2014) Unbiased screen for interactors of leucine-rich
repeat kinase 2 supports a common pathway for sporadic
and familial Parkinson disease. Proc. Natl. Acad. Sci. USA, 111,
2626–2631.
17. Chia, R., Haddock, S., Beilina, A., Rudenko, I.N., Mamais, A.,
Kaganovich, A., Li, Y., Kumaran, R., Nalls, M.A. and Cookson,
M.R. (2014) Phosphorylation of LRRK2 by casein kinase 1a
regulates trans-Golgi clustering via differential interaction
with ARHGEF7. Nat. Commun., 5, 5827.
18. Tong, Y., Giaime, E., Yamaguchi, H., Ichimura, T., Liu, Y., Si,
H., Cai, H., Bonventre, J.V. and Shen, J. (2012) Loss of
leucine-rich repeat kinase 2 causes age-dependent bi-phasic
alterations of the autophagy pathway. Mol. Neurodegener., 7,
2.
19. Schapansky, J., Nardozzi, J.D. and LaVoie, M.J. (2015) The
complex relationships between microglia, alpha-synuclein,
and LRRK2 in Parkinson’s disease. Neuroscience, 302: 74–88.
20. Rivero-Rı´os, P., Go´mez-Suaga, P., Ferna´ndez, B., Madero-
Pe´rez, J., Schwab, A.J., Ebert, A.D. and Hilfiker, S. (2015)
Alterations in late endocytic trafficking related to the patho-
biology of LRRK2-linked Parkinson’s disease. Biochem. Soc.
Trans., 43, 390–395.
21. Law, B.M.H., Spain, V.A., Leinster, V.H.L., Chia, R., Beilina, A.,
Cho, H.J., Taymans, J.-M., Urban, M.K., Sancho, R.M.,
Ramı´rez, M.B. et al. (2014) A direct interaction between
leucine-rich repeat kinase 2 and specific b-tubulin isoforms
regulates tubulin acetylation. J. Biol. Chem., 289, 895–908.
22. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K.
and Abeliovich, A. (2006) The familial Parkinsonism gene
LRRK2 regulates neurite process morphology. Neuron, 52,
587–593.
23. MacLeod, D., Rhinn, H., Kuwahara, T., Zolin, A., Paolo, G.D.,
McCabe, B.D., Marder, K.S., Honig, L.S., Clark, L.N., Small, S.A.
et al. (2013) RAB7L1 interacts with LRRK2 to modify intra-
neuronal protein sorting and Parkinson’s disease risk.
Neuron, 77, 425–439.
24. Sancho, R.M., Law, B.M.H. and Harvey, K. (2009) Mutations in
the LRRK2 Roc-COR tandem domain link Parkinson’s dis-
ease to Wnt signalling pathways. Hum. Mol. Genet., 18,
3955–3968.
25. Imai, Y., Gehrke, S., Wang, H.-Q., Takahashi, R., Hasegawa,
K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by
LRRK2 affects the maintenance of dopaminergic neurons in
Drosophila. EMBO J., 27, 2432–2443.
26. Dorval, V. and He´bert, S.S. (2012) LRRK2 in transcription and
translation regulation: relevance for Parkinson’s disease.
Front. Neurol., 3, 2–7.
27. Pons, B., Armengol, G., Livingstone, M., Lo´pez, L., Coch, L.,
Sonenberg, N. and Ramo´n Y Cajal, S. (2012) Association be-
tween LRRK2 and 4E-BP1 protein levels in normal and malig-
nant cells. Oncol. Rep., 27, 225–231.
28. Nikonova, E.V., Xiong, Y., Tanis, K.Q., Dawson, V.L., Vogel,
R.L., Finney, E.M., Stone, D.J., Reynolds, I.J., Kern, J.T. and
Dawson, T.M. (2012) Transcriptional responses to loss or
gain of function of the leucine-rich repeat kinase 2 (LRRK2)
gene uncover biological processes modulated by LRRK2 ac-
tivity. Hum. Mol. Genet., 21, 163–174.
29. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T.,
Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner,
S. et al. (2011) LRRK2 protein levels are determined by kinase
function and are crucial for kidney and lung homeostasis in
mice. Hum. Mol. Genet., 20, 4209–4223.
30. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R.,
Kelleher, R.J. and Shen, J. (2010) Loss of leucine-rich repeat
kinase 2 causes impairment of protein degradation path-
ways, accumulation of alpha-synuclein, and apoptotic
cell death in aged mice. Proc. Natl. Acad. Sci. USA, 107,
9879–9884.
31. Cookson, M.R. (2015) LRRK2 pathways leading to neurode-
generation. Curr. Neurol. Neurosci. Rep., 15:42.
32. Kuwahara, T., Inoue, K., D’Agati, V.D., Fujimoto, T., Eguchi,
T., Saha, S., Wolozin, B., Iwatsubo, T. and Abeliovich, A.
(2016) LRRK2 and RAB7L1 coordinately regulate axonal mor-
phology and lysosome integrity in diverse cellular contexts.
Sci. Rep., 6, 29945.
3270 | Human Molecular Genetics, 2018, Vol. 27, No. 18
33. Savitski, M.M., Mathieson, T., Zinn, N., Sweetman, G., Doce,
C., Becher, I., Pachl, F., Kuster, B. and Bantscheff, M. (2013)
Measuring and managing ratio compression for accurate
iTRAQ/TMT quantification. J. Proteome Res., 12, 3586–3598.
34. Paradis, H., Islam, T., Tucker, S., Tao, L., Koubi, S. and
Gendron, R.L. (2008) Tubedown associates with cortactin
and controls permeability of retinal endothelial cells to albu-
min. J. Cell Sci., 121, 1965–1972.
35. Sevlever, D., Jiang, P. and Yen, S.H.C. (2008) Cathepsin D is
the main lysosomal enzyme involved in the degradation of
a-synuclein and generation of its carboxy-terminally trun-
cated species. Biochemistry, 47, 9678–9687.
36. Kokkonen, N., Rivinoja, A., Kauppila, A., Suokas, M.,
Kellokumpu, I. and Kellokumpu, S. (2004) Defective acidifica-
tion of intracellular organelles results in aberrant secretion
of cathepsin D in cancer cells. J. Biol. Chem., 279,
39982–39988.
37. Press, B., Feng, Y., Hoflack, B. and Wandinger-Ness, A. (1998)
Mutant rab7 causes the accumulation of cathepsin D and
cation-independent mannose 6-phosphate receptor in an
early endocytic compartment. J. Cell Biol., 140, 1075–1089.
38. Hinkle, K.M., Yue, M., Behrouz, B., Da¨chsel, J.C., Lincoln, S.J.,
Bowles, E., Beevers, J.E., Dugger, B.N., Winner, B., Prots, I.
et al. (2012) LRRK2 knockout mice have an intact dopaminer-
gic system but display alterations in exploratory and motor
co-ordination behaviors. Mol. Neurodegener., 7, 25.
39. Ha¨big, K., Gellhaar, S., Heim, B., Djuric, V., Giesert, F., Wurst,
W., Walter, C., Hentrich, T., Riess, O. and Bonin, M. (2013)
LRRK2 guides the actin cytoskeleton at growth cones to-
gether with ARHGEF7 and Tropomyosin 4. Biochim. Biophys.
Acta Mol. Basis Dis., 1832, 2352–2367.
40. Ohta, E., Nihira, T., Uchino, A., Imaizumi, Y., Okada, Y.,
Akamatsu, W., Takahashi, K., Hayakawa, H., Nagai, M.,
Ohyama, M. et al. (2015) I2020T mutant LRRK2 iPSC-derived
neurons in the Sagamihara family exhibit increased Tau
phosphorylation through the AKT/GSK-3b signaling path-
way. Hum. Mol. Genet., 24, 4879–4900.
41. Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphory-
lates brain tubulin-beta isoforms and modulates microtu-
bule stability—a point of convergence in Parkinsonian
neurodegeneration? J. Neurochem., 110, 1514–1522.
42. Kawakami, F., Shimada, N., Ohta, E., Kagiya, G., Kawashima,
R., Maekawa, T., Maruyama, H. and Ichikawa, T. (2014)
Leucine-rich repeat kinase 2 regulates tau phosphorylation
through direct activation of glycogen synthase kinase-3b.
FEBS J., 281, 3–13.
43. Shanley, M.R., Hawley, D., Leung, S., Zaidi, N.F., Dave, R.,
Schlosser, K.A., Bandopadhyay, R., Gerber, S.A. and Liu, M.
(2015) LRRK2 facilitates tau phosphorylation through
strong interaction with tau and cdk5. Biochemistry, 54,
5198–5208.
44. Ujiie, S., Hatano, T., Kubo, S.-I., Imai, S., Sato, S., Uchihara, T.,
Yagishita, S., Hasegawa, K., Kowa, H., Sakai, F. et al. (2012)
LRRK2 I2020T mutation is associated with tau pathology.
Parkinsonism Relat. Disord., 18, 819–823.
45. Kawakami, F., Yabata, T., Ohta, E., Maekawa, T., Shimada,
N., Suzuki, M., Maruyama, H., Ichikawa, T. and Obata, F.
(2012) LRRK2 phosphorylates tubulin-associated tau but not
the free molecule: lRRK2-mediated regulation of the
tau-tubulin association and neurite outgrowth. PLoS One, 7,
e30834–e30839.
46. Tain, L.S. and Whitworth, A.J. (2009) Translating translation:
regulated protein translation as a biomedical intervention.
Fly (Austin), 3, 278–280.
47. Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.C., Jia, H.,
Stankowski, J., Kim, M.S., Zhong, J., Kumar, M. et al. (2014)
Ribosomal protein s15 phosphorylation mediates LRRK2
neurodegeneration in Parkinson’s disease. Cell, 157, 472.
48. Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M.,
Wachter, S., Lorentzen, E., Duddy, G., Wilson, S. et al. (2016)
Phosphoproteomics reveals that Parkinson’s disease kinase
LRRK2 regulates a subset of Rab GTPases. Elife, 5,
49. Ito, G., Katsemonova, K., Tonelli, F., Lis, P., Baptista, M.A.S.,
Shpiro, N., Duddy, G., Wilson, S., Ho, P.W.-L., Ho, S.-L. et al.
(2016) Phos-tag analysis of Rab10 phosphorylation by LRRK2:
a powerful assay for assessing kinase function and inhibi-
tors. Biochem. J., 473, 2671–2685.
50. Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A.,
Cookson, M.R. and West, A.B. (2018) LRRK2 phosphorylates
membrane-bound Rabs and is activated by GTP-bound
Rab7L1 to promote recruitment to the trans-Golgi network.
HumMol. Genet., 27: 385–395.
51. Liu, Z., Bryant, N., Kumaran, R., Beilina, A., Abeliovich, A.,
Cookson, M.R. and West, A.B. (2018) LRRK2 phosphorylates
membrane-bound Rabs and is activated by GTP-bound
Rab7L1 to promote recruitment to the trans-Golgi network.
Hum. Mol. Genet., 27, 385–395.
52. Jeong, G.R., Jang, E.H., Bae, J.R., Jun, S., Kang, H.C., Park, C.H.,
Shin, J.H., Yamamoto, Y., Tanaka-Yamamoto, K., Dawson,
V.L. et al. (2018) Dysregulated phosphorylation of Rab
GTPases by LRRK2 induces neurodegeneration. Mol.
Neurodegener, 13, 1–17.
53. Feng, M., Hu, X., Li, N., Hu, F., Chang, F., Xu, H. and Liu, Y.
(2017) Distinctive roles of Rac1 and Rab29 in LRRK2 medi-
atedmembrane trafficking and neurite outgrowth. J. Biomed.
Res., 32, 1–12.
54. Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L.,
Xie, C., Long, C.X., Yang, W.J., Ding, J. et al. (2009)
Leucine-rich repeat kinase 2 regulates the progression of
neuropathology induced by Parkinson’s-disease-related
mutant a-synuclein. Neuron, 64, 807–827.
55. Yue, M., Hinkle, K.M., Davies, P., Trushina, E., Fiesel, F.,
Christenson, T., Schroeder, A., Zhang, L., Bowles, E.,
Behrouz, B. et al. (2015) Progressive dopaminergic alterations
and mitochondrial abnormalities in LRRK2 G2019S knock in
mice. Neurobiol. Dis., 78, 172–195.
56. Hauser, D.N., Dillman, A., Ding, J., Li, Y. and Cookson, M.R.
(2014) Post-translational decrease in respiratory chain pro-
teins in the Polg mutator mouse brain. PLoS One, 9,
e94646–e94610.
57. Subramanian, N., Wetzel, A., Dombert, B., Yadav, P.,
Havlicek, S., Jablonka, S., Nassar, M.A., Blum, R. and
Sendtner, M. (2012) Role of nav1.9 in activity-dependent
axon growth in motoneurons. Hum. Mol. Genet., 21,
3655–3667.
58. Perkins, D.N., Pappin, D.J.C., Creasy, D.M. and Cottrell, J.S.
(1999) Probability-based protein identification by searching
sequence databases using mass spectrometry data.
Electrophoresis, 20, 3551–3567.
59. Hastie, T., Tibshirani, R., Narasimhan, B. and Chu, G. (2017)
Package ‘impute’. https://www.bioconductor.org/packages/
devel/bioc/manuals/impute/man/impute.pdf.
60. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false
discovery rate: a practical and powerful approach to multi-
ple testing. J. R. Stat. Soc. B, 57, 289–300.
61. Reimand, J., Arak, T. and Vilo, J. (2011) G: profiler—a web
server for functional interpretation of gene lists (2011 up-
date). Nucleic Acids Res., 39, W307–W315.
3271|Human Molecular Genetics, 2018, Vol. 27, No. 1 8
